Background and objectives Type 2 diabetic patients with end-stage renal disease may receive a simultaneous pancreas-kidney (SPK) transplant. However, outcomes are not well described. Risks for death and graft failure were examined in SPK type 2 diabetic recipients.
Introduction
Simultaneous pancreas-kidney transplantation (SPK) is one of the treatment options for type 1 diabetes mellitus (T1DM) patients with end-stage renal disease (ESRD) (1) . Compared with kidney transplant alone, a successful SPK may improve quality of life (2, 3) , diminish the progression of diabetic complications (4, 5) , and possibly prolong patient and kidney allograft survival (6 -9) . In T1DM, SPK transplant outcomes are excellent, with a reported 5-year patient, kidney, and pancreas graft survival of 88%, 77% (10) , and 69% (11), respectively.
The outcomes of SPK in type 2 diabetes mellitus (T2DM) are less well described and mostly represent single-center experiences. The largest published study included 38 SPK T2DM recipients, defined by a serum C-peptide level Ͼ0.8 ng/ml (12) (13) (14) . In T1DM and T2DM, 5-year patient survival was 85% and 73%, pancreas survival was 71% and 67%, and kidney survival was 77% and 72%, respectively. Another smaller study defined T2DM by a C-peptide level Ն2.0 ng/ml (n ϭ 7) and compared SPK outcomes with T1DM recipients. In T1DM and T2DM, recipients' 3-year patient survival was 94% and 71%, death-censored pancreas survival was 87% and 100%, and deathcensored kidney survival was 95% and 100%, respectively (15) . Two additional studies reported outcomes in T2DM patients with pancreas transplants. One study with 17 recipients (7 were SPK) had 94% pancreas survival in 1 year, and 11 of the 12 recipients were alive and euglycemic after 3 years (16) . The second study included only four SPK transplants, and the outcomes were one death, one pancreas failure within 2 years, and two recipients with euglycemic after 7 years (17) .
In this study we analyzed data from the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS), described characteristics of ESRD T2DM recipients who underwent a SPK transplant in the United States, and compared their outcomes with T1DM recipients. Diabetes was defined based on the diagnosis of end-stage pancreas disease (ESPD) as declared by each pancreas transplant center to UNOS. The objectives of this study were to describe characteristics of T2DM ESRD recipients considered for a SPK and to identify risks for death and graft failure compared with T1DM recipients.
Materials and Methods

Study Population
Using the OPTN/UNOS database as of March 2009, we selected all recipients of a primary SPK transplant between 2000 and 2007. Recipients with a previous kidney-or pancreas-alone transplant were excluded. The cohort was stratified into two groups according to diabetes diagnosis: type 1 and 2 diabetes. Diabetes type definition was taken from the SPK transplant recipient registration form and was based on the diagnosis of ESPD (code 5001 and 5002, corresponding to T1DM and T2DM, respectively). Thirty-three recipients were excluded from the analysis because the cause of ESPD was retransplant/graft failure (n ϭ 7), chronic pancreatitis (n ϭ 1), cystic fibrosis (n ϭ 1), or pancreatectomy (n ϭ 2) and diabetes type other or unknown (n ϭ 22). Only two recipients in the type 1 group were Ͻ18 years old.
Statistical Analyses
Recipient, donor, and transplant baseline characteristics, including immunosuppressive regimens at discharge, were compared. Continuous variables were compared using the Kruskall-Wallis test and categorical variables using the 2 test. The results are shown as median values with 25th to 75th percentile ranges or percentages. Posttransplant events related to the kidney and pancreas allograft were identified and compared between study groups. The transplant date was used as the index date and patients were followed up to a maximum of 5 years after transplant. Kidney, pancreas, and patient survival were compared at the end of this period. Overall kidney graft survival was determined from the time of kidney transplantation until patient death, kidney retransplantation, return to dialysis, or end of follow-up. Overall pancreas graft survival was defined as pancreas failure and patient death. Death-censored graft survival analysis was different from overall survival and did not include patient death as a cause of graft loss. Patient survival was determined from time of kidney transplantation until death or end of follow-up.
The Kaplan-Meier product limit method was used to generate survival curves, logistic regression was used to examine risks associated with posttransplant complications, and Cox regression was used to examine risks associated with graft loss and death. Baseline recipient, donor, and transplant characteristics were treated as potential confounders and were included in the regression model. The multivariate model was constructed using a stepwise method. First, covariates found to have P Յ 0.10 in the univariate analysis were included in the model. After initial covariate interactions, the model was optimized maintaining only the covariates with P Յ 0.05. The variable related with the diabetes type, used to test the association of T2DM versus T1DM with the outcomes, was forced into the model. The results were expressed as odds ratios or hazard ratios with their 95% confidence intervals and associated P values. Risks factors for death and kidney/pancreas failure were also examined separately for type 2 and type 1 diabetics. This analysis intended to define differences in the contribution of similar risk factors for outcomes in a type 1 and 2 diabetic population. Two models were analyzed. The first (model 1) was constructed as described above to the overall cohort, whereas the second (model 2) included a covariate to account for interaction between induction agents and steroid use. All P values were two-tailed and P Ͻ 0.05 was considered significant. STATA version 10 (Statacorp, College Station, TX) was used in all statistical analyses. (Figure 1 ). SPK transplants in type 2 recipients were mainly performed in UNOS regions 2, 3, 5, and 11 ( Figure 2 ).
Results
From
Baseline Characteristics
Recipient, donor, and transplant baseline characteristics according to diabetes type are described in Table 1 . Compared with T1DM recipients, T2DM recipients were older at diabetes onset and at the time of transplant; were more often obese, African American, and Hispanic; had a percent panel of reactive antibodies Ͼ20%; and had a higher pretransplant dialysis time. Type 2 diabetic SPK recipients also had fewer years of diabetes disease, less frequently had private health insurance, and used fewer induction drugs when compared with T1DM patients. The only difference in pretransplant comorbidities was a higher proportion of hypertension in T1DM SPK recipients. Data on average insulin dose used before transplant were available in 2188 of the 6141 T1DM and in 184 of the 582 T2DM recipients. In type 1 and 2 diabetic recipients, the average pretransplant insulin dose was 34 (23.5 to 49) and 30 (17.5 to 45) IU/d, respectively.
Posttransplant Complications
Posttransplant complication rates in T1DM and T2DM recipients are shown in Table 2 . Rates of delayed kidney graft function (11.7% versus 7.8%, P Ͻ 0.001) and kidney primary nonfunction (0.47% versus 1.03%, P ϭ 0.03) were significantly more frequent in the T2DM recipients. Pancreas complications were similar between groups. The adjusted odds ratio (OR) for 1-year cumulative kidney and pancreas acute rejection was 1.19 (95% confidence interval [CI]: 0.99 to 1.43) and for delayed kidney graft function was 1.08 (95% CI: 0.79 to 1.48) for T2DM recipients, with T1DM recipients as the reference. T1DM as the reference. A trend toward increased risk for death-censored kidney graft failure (HR: 1.25; 95% CI: 0.97 to 1.61) was found in the T2DM group. A small but significant increased incidence of graft failure secondary to surgical complication (0.02% [1 of 6141] versus 0.2% [1 of 582], P ϭ 0.04) was seen in T2DM. Risk factors independently associated with outcomes in the overall SPK cohort were shown in Table 3 . The most significant recipient characteristics associated with death were age Ͼ45 years old (versus Յ45 years), Ͼ1 year of pretransplant dialysis (versus pre-emptive), comorbidities such as coronary and peripheral vascular diseases (versus no disease), and exocrine drainage to the bladder (versus enteric). Recipient characteristics associated with kidney and pancreas failure but not with risk of death were AA ethnicity (versus Caucasians) and a body mass index (BMI) Ͼ30 (versus 18.5 to 25). Cold ischemia time Ͼ24 hours (versus Ͻ12 hours) was associated with increased kidney graft failure. Recipients with an HLA mismatch of five to six alleles (versus no mismatch) had a trend toward increased kidney graft failure.
Comparison of Risk Factors for Death, Kidney Failure, and Pancreas Failure between Type 2 and Type 1 Diabetic Recipients
To separately evaluate the contribution of each risk factor to T2DM and T1DM recipients, the Cox regression model was applied to T2DM recipients and then repeated in T1DM recipients. Covariates found to be significant risk factors for the outcomes of T2DM recipients are shown in Table 4 , and their HRs were compared with those found in a T1DM population. Two models (as described in methods) were used in T2DM. In the first model (model 1), recipient age Ͼ45 years old (versus Յ45 years old) and a period of Ͼ1 year on dialysis before transplant (versus pre-emptive transplantation) were associated with increased death. One year or more on dialysis (versus pre-emptive transplantation) and use of alemtuzumab (versus no induction) were associated with increased kidney allograft failure, and a BMI of 25 to 30 and Ͼ30 kg/m 2 (versus BMI of 18.5 to 25 kg/m 2 ) were associated with increased risk for pancreas graft failure. In model 2, a variable to account for the interaction of steroid with induction agent use was included. This further adjusted the risks for kidney failure associated with alemtuzumab use, becoming not associated with increased kidney failure in type Results presented as percent or as median (25th to 75th percentile). Data for BMI missing in 1.4% (n ϭ 95), age of diabetes onset missing in 11.4% (n ϭ 766, 656 in T1DM and 110 in T2DM), PRA missing in 2.6% (n ϭ 178), and HLA mismatch missing in 0.06% (n ϭ 4) of the cohort recipients. PRA, percent of reactive antibodies; EPD, exocrine pancreas drainage; ALG, anti-lymphocyte globulin; OKT 3 , muronab-anti CD3 antibody; ATG, rabbit anti-thymocyte globulin; IL2-RA, interleukin 2 receptor antibody (basiliximab and daclizumab); AP, antiproliferative; MMF, mycophenolate mofetil (includes nonenteric and enteric formulations); SRL, sirolimus; AZA, azathioprine; CAD, coronary artery disease; CVD, cerebrovascular disease; PVD, peripheral vascular disease; COD, cause of death; CIT cold ischemia time.
2 recipients and associated with decreased failure in type 1 diabetic recipients. When we compared risks between recipients with diabetes diagnosis (Table 4) , we found that in T2DM and T1DM, risk for patient death increased respectively in 116% and 29% with an older recipient age and in 160% and 59% with a pretransplant dialysis time Ͼ1 year. Pretransplant dialysis Ͼ1 year also increased the risk for overall kidney graft loss in 148% and 25% in T2DM and T1DM, respectively, and obesity was associated with a 71% and 27% increased risk for pancreas failure in T2DM and T1DM recipients, respectively. Recipient age, time on dialysis pretransplant, and BMI may have been the covariates responsible for adjusting risks in T2DM and for determining that T2DM recipients had a risk for SPK outcomes similar to T1DM recipients.
Discussion
We studied characteristics and outcomes of all SPK recipients between the years 2000 and 2007 in the United States diagnosed as T2DM according to the pancreas transplant center. The large size of our cohort (n ϭ 582) when compared with previous single-center reports allowed us to examine adjusted risks for death and kidney/pancreas failure associated with diabetes diagnosis (T1DM or T2DM).
In contrast to previous studies (13-15), we did not find a significant difference in patient survival between T1DM and T2DM recipients. Also, after adjustments, T2DM was not associated with increased death when compared with T1DM recipients. In T2DM recipients, older age and a longer pretransplant dialysis time were associated with higher risks for death than in T1DM recipients. These differences have to be taken in account when comparing survival. Comorbidities developed during dialysis time may be more intense in T2DM than in T1DM recipients (18 -20) . However, this is speculative because there are few studies comparing dialysis outcomes between T1DM and T2DM with ESRD. Overall, in insulin-dependent ESRD candidates for a SPK transplant, cardiovascular disease and time on waitlist were identified as potentially modifiable risks for death.
There is a concern that the insulin resistance in T2DM recipients would lead to an increase in pancreas allograft insulin production with ␤ cell exhaustion and a decrease in the pancreas functional survival (21) . However, neither our study or previous studies support increased pancreas graft failure in T2DM. We found that 5-year pancreas survival in T2DM was 69.8%, comparable to the 72.4% in T1DM recipients. Light et al. found a 5-year pancreas survival of 67% in T2DM and of 71% in T1DM (12) . Nath et al. showed a 1-year pancreas survival of 94% in T2DM (16) . In our study T2DM was not an independent risk factor for pancreas failure even after adjusting for other risk factors. Only the Light et al. study reported long-term pancreas survival (10 years), with a pancreas survival of 49% and 56% in their T1DM and T2DM recipients, respectively. Additional long-term follow-up trials are needed to study pancreas allograft survival related to diabetes type. In our study, the two main covariates associated with increased pancreas failure were older donor age and higher BMI of the recipient. Risk for pancreas failure associated with BMI was particularly high in T2DM. We cannot examine why increased BMI was a stronger predictor of pancreas failure in T2DM patients compared with T1DM patients. However, we can hypothesize that in T2DM recipients increased BMI may be a marker of plurimetabolic syndrome, with insulin resistance, hyperinsulinemia, dyslipidemia, vascular disease, and increased prothrombotic activity that may contribute to pancreas loss (22) (23) (24) (25) (26) .
Regarding kidney survival, we found an inferior 5-year overall (77.8% versus 73.5%; P ϭ 0.007) and deathcensored survival (85.3% versus 82.9%, P ϭ 0.04) in T2DM when compared with T1DM. However, after adjusting for other potential risk factors, diabetes type was not confirmed as an independent risk factor for kidney graft failure. Risks for kidney and pancreas failure in overall insulin-dependent recipients were most importantly associated with AA race (versus Caucasian) and obesity (versus normal BMI). This was not a surprise because AA race was associated with increased risk of nonimmune and immune posttransplant complications (27) , and obesity has been shown to be a potential risk for posttransplant complications in T1DM (28) . In nontransplant surgery, obese patients were more likely to have increased surgical time and blood loss during the procedure (29, 30) . The former can lead to prolonged cold ischemia time and the latter to hypotensive episodes during or after the surgery. Both complications may predispose to delayed kidney graft failure or allograft thrombosis. In line with this, we found a higher rate of delayed kidney graft function and primary kidney nonfunction in the T2DM group, which has a higher percentage of overweight and obese recipients when compared with T1DM recipients. When comparing hazards for graft failure between T2DM and T1DM recipients, time on dialysis was found to be the main confounder responsible for adjusted risk for kidney allograft failure in T2DM.
The main limitation of our study is the lack of specific information on the criteria used to define diabetes type. Diabetes diagnosis reported in the UNOS prepancreas transplant forms reflects current practice in U.S. pancreas transplant centers. It may include laboratorial parameters in association with clinical judgment; however, we could not validate the reported diagnosis. Diabetes type diagnosis in ESRD patients relies mainly on the clinical history (31) , and therefore occasional misdiagnoses can be expected. The antibody anti-glutamic acid decarboxylase has been studied as a marker to differentiate T2DM from latent autoimmune diabetes in adults, and it has been shown that 2% to 12% of patients initially diagnosed as T2DM in fact had latent autoimmune diabetes (32) . On the basis of this information, our diabetes classification may incur an incorrect diagnosis of T2DM not over 12%. Anti-glutamic acid decarboxylase may be used at diabetes onset; however, it has yet to be validated as a reliable diagnosis tool several years after the diabetes onset, as is the case when ESRD diabetics are listed for a SPK transplant. C-peptide level as an isolated parameter is unreliable for diabetes diagnosis in ESRD patients (33, 34) . Others limitations to the study are that criteria for pancreas allograft failure are poorly described in UNOS. In general, pancreas graft failure is assumed when a recipient returns to exogenous insulin after a period of insulin independence. Finally, our study is limited by missing records and a potential selection bias of recipients that can be found in retrospective analyses.
In conclusion, 9% of all SPK transplants between 2000 and 2007 in the United States were done in recipients diagnosed with T2DM. Compared with recipients diagnosed with T1DM, type 2 diabetic recipients had a higher proportion of associated comorbidities. However, after adjusting for other risk factors, T2DM was associated with similar risks for death and kidney or pancreas failure after a SPK transplant when compared with T1DM recipients.
